The VEGF-A or VEGFR-2 inhibitors that have been approved for the treatment of NSCLC in Japan include bevacizumab, which binds VEGF-A and inhibits its activity, and ramucirumab, which binds VEGFR-2 and inhibits its activity. This evidence concerns the gene KDR and non-small cell lung carcinoma.